Experts believe a pioneering breakthrough by a Manchester hospital research team could pave the way for doctors to better understand and treat adults with Cystic Fibrosis (CF), helping them live longer and healthier lives. http://www.medicalnewstoday.com/releases/262897.php Continue reading Manchester Researchers Discover Half Of All Adults With Cystic Fibrosis Affected By Airborne Fungus
Pharmaxis Limited (ASX:PXS) has presented new analyses on the longer term benefits of its drug Bronchitol on cystic fibrosis sufferers.
The presentation at the European Cystic Fibrosis Society conference in Portugal, included the Continue reading Pharmaxis’ new drug progress in EU
It’s been nearly two and a half decades since the gene associated with the inherited disease cystic fibrosis was discovered, paving the way for disease-modifying drugs. In that time, only one such drug has been approved in the U.S. and Europe – Vertex’s Kalydeco. And that drug is only Continue reading For new Rhode Island firm, peptides hold hope for disease-altering cystic fibrosis treatments
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, today presented data on the Company’s preclinical targets for Parkinson’s disease and cystic fibrosis at a Continue reading Proteostasis Therapeutics Presents Preclinical Data on Parkinson’s Disease and Cystic Fibrosis Targets at EMBO Conference
N30 Pharmaceuticals, Inc., a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis (CF), announced today the presentation of key preclinical data for its novel inhibitors of S-nitrosoglutathione reductase (GSNORi). The data were Continue reading N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
U.S. health regulators approved on Friday a hand-held inhaler made by Swiss drug maker Novartis AG to treat a type of bacterial lung infection that often affects cystic fibrosis patients.
Novartis’s TOBI Podhaler contains a dry powder formulation of tobramycin, an antibiotic used to Continue reading U.S. FDA OKs Novartis inhaler to treat lung infection in cystic fibrosis patients
Mar 19, 2013 – The US Food and Drug Administration (FDA) has completed its review of Pharmaxis’ New Drug Application (NDA) for its dry powder formulation of mannitol (Bronchitol, Pharmaxis) and has recommended that the company conduct an additional study to obtain Continue reading FDA Sends Cystic Fibrosis Treatment Back for More Study
Published on March 1, 2013 at 12:00 AM
Chronic or acute, liver failure can be deadly. Toxins take over, the skin turns yellow and higher brain function slows.
“There is no effective therapy at the moment to deal with the toxins that build up in your body,” Continue reading Stem cell line could also advance research into liver cancers, cystic fibrosis
Vertex Pharmaceuticals (VRTX) announced Tuesday night the design of two phase III studies for its combination therapy to treat the most common form of cystic fibrosis. The studies will each run for six months, so results could be ready as early as the end of 2013 or during first half of 2014.
If the studies are positive, Vertex intends to file for U.S. approval in 2014. Continue reading Vertex Readies Late-Stage Cystic Fibrosis Drug Studies
Promising pre-clinical data in Cystic Fibrosis for ProtAffin AGs PA401 to be presented at ATS, Philadelphia, 17-22 May 2013
ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for inflammation, respiratory disease and oncology, has announced that a collaboration with a leading European centre for the study of cystic fibrosis has generated Continue reading Pharma And Biotech